Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use.

Grzankowski, Kassondra S; Szender, J Brian; Spring-Robinson, Chandra L; Lele, Shashikant B; Odunsi, Kunle O; Frederick, Peter J

Grzankowski, Kassondra S; Szender, J Brian; Spring-Robinson, Chandra L; Lele, Shashikant B; Odunsi, Kunle O; Frederick, Peter J.

Affiliation

Grzankowski KS; *Department of Gynecologic Oncology, Roswell Park Cancer Institute; Department of Obstetrics and Gynecology, State University of New York at Buffalo; and Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY.

Int J Gynecol Cancer ; 26(8): 1440-7, 2016 10.

Article in En | MEDLINE | ID: mdl-27648713

Subject(s)

Breast Neoplasms/drug therapy; Endometrial Neoplasms/drug therapy; Neoplasms, Second Primary/drug therapy; Tamoxifen/administration & dosage; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal/administration & dosage; Breast Neoplasms/diagnosis; Breast Neoplasms/epidemiology; Chemotherapy, Adjuvant; Endometrial Neoplasms/diagnosis; Endometrial Neoplasms/epidemiology; Female; Humans; Middle Aged; Neoplasms, Second Primary/diagnosis; Neoplasms, Second Primary/epidemiology; Time Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tamoxifen / Breast Neoplasms / Neoplasms, Second Primary / Endometrial Neoplasms Type of study: Diagnostic_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Int J Gynecol Cancer Journal subject: GINECOLOGIA / NEOPLASIAS Year: 2016 Type: Article

Fulltext

XML

PubMed Links

Search on Google